Exicure, Inc. (NASDAQ:XCUR) Sees Significant Decrease in Short Interest

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totalling 34,300 shares, a decline of 23.3% from the March 15th total of 44,700 shares. Currently, 1.4% of the shares of the stock are short sold. Based on an average daily volume of 62,000 shares, the short-interest ratio is currently 0.6 days.

Exicure Stock Performance

Shares of XCUR stock opened at $8.44 on Monday. The company has a market capitalization of $53.32 million, a PE ratio of -4.08 and a beta of 3.74. Exicure has a 52-week low of $1.44 and a 52-week high of $36.00. The business’s fifty day moving average is $11.27 and its 200 day moving average is $11.03.

Exicure (NASDAQ:XCUR) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($3.39) earnings per share for the quarter.

Hedge Funds Weigh In On Exicure

A hedge fund recently bought a new stake in Exicure stock. Geode Capital Management LLC purchased a new stake in shares of Exicure, Inc. (NASDAQ:XCUR) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 12,645 shares of the company’s stock, valued at approximately $173,000. Geode Capital Management LLC owned approximately 0.48% of Exicure as of its most recent SEC filing. 42.82% of the stock is currently owned by institutional investors and hedge funds.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.